Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Recce Pharmaceuticals Ltd. ( (AU:RCE) ).
Recce Pharmaceuticals Ltd held its 2025 Annual General Meeting, where all resolutions were decided by poll. Notably, the re-election of Dr. John Prendergast and Dr. Justin Ward as directors was carried, while resolutions related to the future issue of securities and ratification of prior share and warrant issues were not carried. The outcome of the meeting, including a ‘first strike’ against the remuneration report, may impact the company’s governance and future strategic decisions.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their product pipeline includes patented, broad-spectrum anti-infectives such as RECCE 327, RECCE 435, and RECCE 529, which are designed to treat serious bacterial and viral infections. The company has received recognition from the World Health Organization and the FDA for its efforts in addressing antimicrobial resistance.
Average Trading Volume: 131,668
Technical Sentiment Signal: Hold
Current Market Cap: A$115.7M
Learn more about RCE stock on TipRanks’ Stock Analysis page.